Executive Director
Alexion
Executive Director
Alexion
Global biopharmaceuticals focusing on rare diseases
This is what you will do:
The Executive Director, Head of Sales NF1 will be responsible for all sales activities related to the NF1 business for the entire US market. The candidate will lead a team of Regional Sales Directors in executing marketing strategies, achieving annual sales goals and growth expectations. This position reports to the VP of the US Rare Endocrinology & Rare Tumors Business Unit.
You will be responsible for:
You will need to have:
We would prefer for you to have:
Date Posted
13-Nov-2026Closing Date
26-Nov-2026Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion